[1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic...

Details [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic... [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic...

2006-03-14

2006-03-14

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S411000, C540S472000

Reexamination Certificate

active

07012089

ABSTRACT:
Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided:where R1through R7are defined herein. The compounds of formula (I) are 5HT2c agonists or partial agonists, and are useful for treating a variety of disorders.

REFERENCES:
patent: 3158619 (1964-11-01), Wagner
patent: 3235564 (1966-02-01), Wagner et al.
patent: 3296252 (1967-01-01), Frey et al.
patent: 3329676 (1967-07-01), Bell et al.
patent: 3335134 (1967-08-01), Frey et al.
patent: 3417101 (1968-12-01), Bell et al.
patent: 3466274 (1969-09-01), de Ridder
patent: 3714149 (1973-01-01), Hester, Jr.
patent: 3914250 (1975-10-01), Kim
patent: 4880814 (1989-11-01), Chu et al.
patent: 4997831 (1991-03-01), Bays et al.
patent: 5045545 (1991-09-01), Bays et al.
patent: 5834454 (1998-11-01), Kitano et al.
patent: 6414144 (2002-07-01), Welmaker et al.
patent: 6503900 (2003-01-01), Sabb et al.
patent: 2002/0055504 (2002-05-01), Chan
patent: 2002/0058689 (2002-05-01), Welmaker et al.
patent: 2002/0062022 (2002-05-01), Sabb et al.
patent: 2002/0107242 (2002-08-01), Sabb et al.
patent: 2002/0119966 (2002-08-01), Sabb et al.
patent: 2002/0128261 (2002-09-01), Sabb et al.
patent: 2002/0173503 (2002-11-01), Robichand et al.
patent: 2003/0050300 (2003-03-01), McWhorter, Jr.
patent: 2004/0009970 (2004-01-01), Wyeth
patent: 2004/0019040 (2004-01-01), Wyeth
patent: 0 344 015 (1989-11-01), None
patent: 0 357 417 (1990-03-01), None
patent: 02-040379 (1990-02-01), None
patent: 10-237073 (1998-09-01), None
patent: 2001-89461 (2001-04-01), None
patent: 930902 (1982-11-01), None
patent: WO 90/15058 (1990-12-01), None
patent: WO 96/29316 (1996-09-01), None
patent: WO 97/30999 (1997-08-01), None
patent: WO 97/31000 (1997-08-01), None
patent: WO 99/66934 (1999-12-01), None
patent: WO 99/67219 (1999-12-01), None
patent: WO 00/35922 (2000-06-01), None
patent: WO 00/40226 (2000-07-01), None
patent: WO 00/64899 (2000-11-01), None
patent: WO 00/77002 (2000-12-01), None
patent: WO 01/12602 (2001-02-01), None
patent: WO 01/12603 (2001-02-01), None
patent: WO 01/64246 (2001-09-01), None
patent: WO 02/08186 (2002-01-01), None
patent: WO 02/36596 (2002-05-01), None
patent: WO 02/42304 (2002-05-01), None
patent: WO 02/059124 (2002-08-01), None
patent: WO 02/059129 (2002-08-01), None
Gregory E. Martin et al., J. Med. Chem., 32, 1052-1056 (1989).
J.L. Browning et al., Society for Neuroscience Abstracts, 25(2), 2075, Abstract 830.12, (1999).
Jackson B. Hester et al., J. Med. Chem., 13, 827-835 (1970).
Dong H. Kim, J. Heterocycl. Chem., 13(6), 1187-1192 (1976).
H.P. Haerter et al., Chimia, 30, 50-52 (1976).
Oliver H. Lowry et al., J. Biol. Chem., 193, 265-275 (1951).
Samuel H. Wilen, et al., Tetrahedron, 33, 2725-2736 (1977).
Shunji Naruto et al., Tetrahedron Letters, 39, 3399-3402 (1975).
Giuseppe Digiovanni et al., Synapse, 35, 53-61 (2000).
Vincenzo Dimatteo et al., Neuropharmacology, 37, 265-272 (1998).
Vincenzo Dimatteo, et al., Neuropharmacology, 38, 1195-1205 (1999).
M.J. Millan et al., Neuropharmacology, 37, 953-955 (1998).
Prakash S. Masand, Exp. Opin. Pharmacother, 1(3), 377-389 (2000).
David B. Allison et al., Am. J. Psychiatry, 156(11), 1686-1696 (1999).
P.J. Cowan et al., Human Psychopharmacology, 10, 385-391 (1995).
A. Schotte et al., Psychopharmacology, 124, 57-73 (1996).
Susan H. Fox et al., Experimental Neurology, 151, 35-49 (1998).
R. Whitaker, Spectrum, 2, 1-12 (2000).
Katsunori Nonogaki et al., Nature Medicine, 4(10) 1152-1156 (1998).
Laurence H. Tecott et al., Nature, 374, 542-546 (1995).
P.A. Sargent et al., Psychopharmacology, 133, 309-312 (1997).
M.J. Piesla et al., International Congress on Schizophrenia Research (2001).
Craig D. Applegate et al., Experimental Neurology, 154, 522-530 (1998).
Mark J. Millan et al., European Journal of Pharmacology, 325, 9-12 (1997).
Andrew J. Grottick et al., The Journal of Pharmacology & Experimental Therapeutics, 295(3), 1183-1191 (2000).
Duckhyun Kim et al., Experimental Neurology, 169, 496-500 (2001).
Roger M. Nitsch et al., The Journal of Biological Chemistry, 271(8), 4188-4194 (1996).
J.R. Martin et al., The Journal of Pharmacology & Experimental Therapeutics, 286(2), 913-924 (1998).
Marie-Christine Buhot, Current Opinion in Neurobiology, 7, 243-254 (1997).
Yuhao Li et al., European Journal of Pharmacology, 392, 71-77 (2000).
Jason Bennett et al., www.emedicine.com, “Delusional Disorder” (Apr. 2002).
Sharon Rosenzweig-Lipson et al., “Antipsychotic-like Effects of the 5-HT2cSelective Agonist WAY-163909 in Rodents”, Serotonin Symposium-EPHAR, Porto, Portugal, (Jul. 2004).
Michael First, Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, Mood Disorders, Introduction, Adjustment Disorders, American Psychiatric Assoc. (2000).
Sharon Rosenzweig-Lipson et al., “Antidepressant-like Effects of the 5-HT2cSelective Agonist WAY-163909 in Rodents”, Serotonin Symposium-EPHAR, Porto, Portugal, (Jul. 2004).
Sharon Rosenzweig-Lipson et al., “Pharmacological Characterization of WAY-163909, a Novel 5-HT2cReceptor Selective Agonist”, Serotonin Symposium-EPHAR, Porto, Portugal, (Jul. 2004).
A.N. Grinev et al., Chem. Heterocycl. Compd., 19(9), 959-961 (1983).
A.N. Grinev et al., Chem. Heterocycl. Compd., 19(12), 1312-1315 (1983).
E.V. Lamanova et al., Pharm. Chem., J., 23(2), 113-115 (1989).
D.H. Kim et al., Journal of Medicinal Chemistry, 20(2), 209-212 (1977).
D.H. Kim, J. Heterocyclic Chem., 13, 1187-1192 (1976).
L. Toscano et al., J. Heterocyclic Chem., 13, 475-480 (1976).
A. Katritzky et al., Synthesis, 10, 1487-1490 (1998).
F. Gatta et al., Edizione Scientifica, 30(8), 631-641 (1975).
W. Lopes et al., Journal of Brazilian Chemical Society, 4(1), 34-39 (1993).
S. Rosenzweig-Lipson et al., The FASEB Journal, 14, A1321 (2000).

Affiliated with

Also associated with

Rating

[1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and [1,4]Diazocino[7,8,1-hi]indole derivatives as antipsychotic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3524215